BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels
BridgeBio presented new exploratory cardiac data from the Phase 3 FORTIFY trial of BBP-418 in LGMD2I/R9, showing 100% of treated patients with elevated HS troponin I returned to normal range by Month 12 versus 40% on placebo (p=0.0248). Additionally, 54% of BBP-418-treated participants had stable or improved LVEF versus 25% on placebo (p=0.0262), and glycosylated αDG rose to levels seen in asymptomatic FKRP carriers — a pattern the company says supports disease-modifying potential.
Key figures
- Drug Name
- BBP-418
- Phase Of Trial
- Phase 3
- Pdufa date
- November 27, 2026
- Trial name
- FORTIFY
- Lvef stable or improved
- 54% BBP-418 vs 25% placebo (p=0.0262)
- Hs troponin normalization
- 100% BBP-418 vs 40% placebo (p=0.0248)
- Addressable patients us eu
- 7000
- Ls mean troponin difference
- -17.8 ng/L
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.